 Angel Biotechnology | Customised Biopharmaceutical Solutions | Annual Report & Accounts for the period ended 31 March 2012 12
Directors' Remuneration Report
The Company recognises the value of the Combined Code on Corporate 
Governance issued by the London Stock Exchange. It seeks to comply 
with the Combined Code so far as practicable and appropriate for a 
public company of its size and nature.
The Remuneration Committee of the board is 
responsible for considering staff and Directors' 
remuneration packages and makes its recommendations 
to the board. The Committee comprises the Chairman 
and two Non-Executive Directors. It meets at least once 
a year to review salaries and share option schemes for 
staff and Directors.
Remuneration policies
Remuneration packages are designed to be competitive 
and to reward above average performances. At present 
Executive Directors receive salary and a 10-12% pension 
contribution. The Acting Chief Executive Officer is 
entitled to a performance related bonus. He also holds 1 
grant of share options issued on 21 February 2012.  
The vesting criteria of these options include both 
retention and performance targets.
Service contracts
The Executive Directors have executive service 
agreements with the Company. The service agreements 
are subject to termination with six months' notice being 
given by either party.
Pensions
The Company operates a defined contribution pension 
scheme for employees.
Share Option Scheme
The Company operates an HM Revenue & Customs 
approved EMI share option scheme that entitles 
directors, senior management and employees to 
purchase shares in the Company.  
Grants of share options have been awarded in 2005, 
2010, 2011 and 2012.  The options are exercisable at the 
market price of the shares at the date of grant.
During the period 37,545,852 share options were granted 
to directors.
Non-executive Directors
The Non-Executive Directors have entered into letters of 
engagement with the Company. Members may request 
copies of these letters by sending a stamped addressed 
envelope to the Company Secretary. The appointments 
can be terminated upon six months' notice being given 
by either party. 
Directors' remuneration 
Details of Directors' remuneration in the 15 month period ended 31 March 2012 is 
set out below:
 Emoluments Pension Total 
      
Executive 
Dr P Harper 68,030 - 68,030
G Sherriff 139,000 15,300 154,300
L Peers 83,062 1,425 84,487
Dr S White 26,885 - 26,885
Non-executive
G Clark 16,667 - 16,667
N Smith 16,667 - 16,667
Total 350,311 16,725 367,036
Emoluments to N Smith were paid to Eurowater Ltd and for G Clark were paid to 
Marlin Bioconsulting Ltd.
Two directors accrued benefits under the defined contribution pension scheme.
Directors Share Options 
 Options at  Options Options at Exercise Exercise Expiry 
 31.12.10 granted  31.03.12 Price (p) Period Date 
  in period
Dr P Harper 3,107,410 - 3,107,410 0.22 10 years 29/07/20
Dr P Harper - 4,347,826 4,347,826 0.23 10 years 11/08/21
G Sherriff 16,901,408 - 16,901,408 0.22 10 years 29/07/20
G Sherriff 550,000 - 550,000 0.50 10 years 19/07/15
G Sherriff - 4,434,782 4,434,782 0.23 10 years 11/08/21
L Peers - 3,260,869 3,260,869 0.23 10 years 11/08/21
Dr S White - 16,806,723 16,806,723 0.23 10 years 20/02/22
G Clark 5,633,802 - 5,633,802 0.22 10 years 29/07/20
G Clark - 4,347,826 4,347,826 0.23 10 years 11/08/21
N Smith 5,633,802 - 5,633,802 0.22 10 years 29/07/20
N Smith - 4,347,826 4,347,826 0.23 10 years 11/08/21
The market price of the shares at 31 March 2012 was 0.20p and the range during 
the period was 0.20p to 0.31p.
By order of the board
Dr Paul Harper
Chairman
31 May 2012